Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia

Authors: Thomas, Xavier¹; Dombret, Hervé²

Source: Hematology, Volume 12, Number 1, February 2007 , pp. 15-28(14)

Buy & download fulltext article:

Price: $48.00 plus tax (Refund Policy)

Abstract:

Increasing the intensity of induction chemotherapy has generated considerable recent interest in the treatment of acute myeloid leukemia. Achieving complete remission is a sine qua non condition for prolonged disease-free survival and may affect long-term outcome. In this setting, administering a repeat course of induction shortly after completion of the first course, known as timed-sequential chemotherapy (TSC), has been tested and may lead to an improved long-term outcome. Whether these results are due to the biologic recruitment of cell cycle-specific agents is unknown. However, this strategy to intensify induction may lead to more profound myelosuppression and to potential toxicities. Here we review the results of timed-sequential chemotherapy, used as induction regimen in de novo, relapsed or refractory AML or used as post-remission therapy, and compare them with those from other types of regimens.

Keywords: ACUTE MYELOGENOUS LEUKEMIA; PROGNOSIS; INDUCTION REGIMEN; TIMED-SEQUENTIAL CHEMOTHERAPY

Document Type: Research Article

DOI: http://dx.doi.org/10.1080/10245330600938240

Affiliations: 1: Leukemia Unit, Hematology Department, Edouard Herriot, Hospital, Lyon, France 2: Leukemia Unit, Hematology Department, Saint-Louis Hospital, Paris, France

Publication date: 2007-02-01

More about this publication?